NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT ID: NCT05247957

Last Updated: 2023-01-13

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-13
• Study Completion Date: 2022-12-20

Brief Summary

This trial will explore the maximum tolerated dose of cord blood NKG2D CAR-NK in the treatment of recurrent refractory acute myeloid leukemia in a dose-escalation manner, and observe its clinical safety and efficacy.

Detailed Description

This is a single arm, open-label, Phase 1 study initiated with 3 cohorts:

Cohort 1: 2×10∧6/kg CAR-NK cells, 2 infusions on Day 0 and Day 7 Cohort 2: 6×10∧6/kg CAR-NK cells, 2 infusions on Day 0 and Day 7 Cohort 3: 18×10∧6/kg CAR-NK cells, 2 infusions on Day 0 and Day 7

Conditions

Safety and Efficacy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

NKG2DL-specific CAR-NK cells

Experimental: NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7 After preconditioning with chemotherapy, NKG2DL-specific CAR-NK cells will be evaluated

Group Type: EXPERIMENTAL

CAR-NK cells

Intervention Type: BIOLOGICAL

NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7

Interventions

CAR-NK cells

NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7

Intervention Type: BIOLOGICAL

Other Intervention Names

NKG2DL-specific CAR-NK cells

Eligibility Criteria

Inclusion Criteria

1. Age: ≥ 10 years old and ≤ 75 years old, male or female;

2. Meet the diagnostic criteria for recurrent AML: detection of leukemia cells after complete remission (CR) or >0.1% of leukemia cells in bone marrow, including recurrence after allogeneic hematopoietic stem cell transplantation, or extramedullary infiltration of leukemia cells;

3. Initial cases with failure of 2 lines of standard treatment; patients who relapsed within 12 months after consolidation intensification after CR; recurrence in 12 months and no respond to conventional chemotherapy; 2 or more recurrences; persistent extramedullarial leukemia;

4. Patients currently have no effective treatment options, such as chemotherapy or allogeneic hematopoietic stem cell transplantation, or patients voluntarily choose to infuse NKG2D CAR-NK cells as the first treatment option;

5. Physical status assessment (ECOG-PS) of the Eastern Oncology Collaborative Group is 0-2 points;

6. Estimated survival > 3 months

7. Flow cytometry check for NKG2D ligand expression on the surface of cancer cells for a reference of selecting patients

8. The main organs of the patient are well functioned: (1) cardiac function: no heart disease or coronary heart disease, the patient's cardiac function grade 1-2; (2) liver function: TBIL≦3ULN, AST≦2.5ULN, ALT≦2.5ULN; (3) Renal function: Cr≦1.25ULN;

9. The patient's peripheral superficial vein can meet the needs of intravenous injection;

10. No other serious diseases that conflict with this protocol (e.g., autoimmune diseases, immunodeficiency, organ transplantation);

11. No history of other malignant tumors;

12. Women of childbearing age must be tested negative for pregnancy within 7 days, and subjects of childbearing age must use appropriate contraception during both the trial and for 3 months after the test;

13. Subjects have negative HIV, HBV, HCV, syphilis serology test results

14. Written informed consent form must be signed before enrollment.

Exclusion Criteria

1. Acute promyelocytic leukemia (type M3);

2. Patients with cardiac insufficiency, patients with hepatic and renal insufficiency;

3. Those who need treatment with other malignant tumors;

4. Poorly controlled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg) or clinically significant cardiovascular and cerebrovascular diseases such as cerebrovascular accident (within 6 months before signing the informed consent form), myocardial infarction (within 6 months before signing the informed consent), unstable angina, congestive heart failure, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on research treatment;

5. Also suffering from other hematologic diseases (such as hemophilia, myelofibrosis, etc., which researchers consider unsuitable for inductees);

6. Diffuse vascular internal coagulation;

7. Concomitant serious infection or other serious underlying medical condition;

8. Have immunodeficiency and autoimmune diseases;

9. Have severe allergic diseases;

10. Clinical symptoms of brain dysfunction or severe mental illness that can not understand or follow the research protocol;

11. Have participated in clinical trials of other drugs within 4 weeks or within 21 days of surgery;

12. Have received cell therapy in the previous 1 month;

13. Have received hormonal drug therapy in the previous 14 days;

14. Known HIV-positive patients or hepatitis B and C patients and syphilis patients;

15. Have received organ transplants (excluding stem cell transplant patients);

16. Drug abuse, medical, psychological or social conditions that may interfere with a subject's participation in the study or evaluation of the results of the study;

17. Pregnant or lactating women;

18. Those who cannot be followed up as scheduled;

19. Investigator considers that the subject has any clinical or laboratory abnormalities or compliance problems and is not suitable to participate in this clinical study.

• Minimum Eligible Age: 10 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hangzhou Cheetah Cell Therapeutics Co., Ltd

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peihua Lu, MD

Role: PRINCIPAL_INVESTIGATOR

Hebei Yanda Lu Daopei Hospital

Locations

Hebei Yanda Lu Daopei Hospital

Sanhe, Hebei, China

Countries

China

Other Identifiers

CARNK-001

Identifier Type: -

Identifier Source: org_study_id